tiprankstipranks
Advertisement
Advertisement
Rani Therapeutics reports Q1 EPS (4c), consensus (5c)
PremiumThe FlyRani Therapeutics reports Q1 EPS (4c), consensus (5c)
15d ago
Edward Nash Reiterates Buy on Rani Therapeutics, Maintains Unchanged $5 Price Target Amid Encouraging RT-114 and Oral Biologics Platform Outlook
Premium
Ratings
Edward Nash Reiterates Buy on Rani Therapeutics, Maintains Unchanged $5 Price Target Amid Encouraging RT-114 and Oral Biologics Platform Outlook
23d ago
Rani Therapeutics price target lowered to $5 from $9 at Canaccord
Premium
The Fly
Rani Therapeutics price target lowered to $5 from $9 at Canaccord
2M ago
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
4M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
4M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
4M ago
Rani Therapeutics files to sell 42.63M shares of Class A common stock for holder
PremiumThe FlyRani Therapeutics files to sell 42.63M shares of Class A common stock for holder
7M ago
Rani Therapeutics Reports Financial Challenges Amid Innovation
Premium
Company Announcements
Rani Therapeutics Reports Financial Challenges Amid Innovation
7M ago
Rani Therapeutics reports Q3 EPS (12c), consensus (12c)
Premium
The Fly
Rani Therapeutics reports Q3 EPS (12c), consensus (12c)
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100